Analysis of The Cancer Genome Atlas database showed that FXYD3 was upregulated in breast cancer tissues and not in normal tissues (Supplemental Figure 5C), and breast cancer patients with high FXYD3 expression showed poor prognosis (Supplemental Figure 5D). This evidence concerns the gene FXYD3 and breast carcinoma.